Moderna Revenue

MRNA
 Stock
  

USD 159.56  4.02  2.58%   

Moderna fundamentals help investors to digest information that contributes to Moderna's financial success or failures. It also enables traders to predict the movement of Moderna Stock. The fundamental analysis module provides a way to measure Moderna's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Moderna stock. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  
Refresh
Moderna Deferred Revenue is projected to increase significantly based on the last few years of reporting. The past year's Deferred Revenue was at 6.87 Billion. The current year Revenues is expected to grow to about 19.9 B, whereas Cost of Revenue is forecasted to decline to about 2.1 B.

Moderna Revenue Analysis

Moderna's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Moderna Revenues

19.93 Billion

Revenue 
 = 
Money Received 
Discounts and Returns 
More About Revenue | All Equity Analysis

Current Moderna Revenue

    
  18.47 B  
Most of Moderna's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Moderna is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Moderna Revenue Driver Correlations

Understanding the fundamental principles of building solid financial models for Moderna is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Revenue. Since Moderna's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Moderna's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Moderna's interrelated accounts and indicators.

Moderna Revenue Historical Pattern

Today, most investors in Moderna Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Moderna's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Moderna revenue as a starting point in their analysis.
 Moderna Revenue 
Share
      Timeline 
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Compare to competition

Moderna Deferred Revenue

Deferred Revenue

7.41 Billion

Moderna Deferred Revenue is projected to increase significantly based on the last few years of reporting. The past year's Deferred Revenue was at 6.87 Billion
Based on the latest financial disclosure, Moderna reported 18.47 B of revenue. This is 142.17% higher than that of the Healthcare sector and significantly higher than that of the Biotechnology industry. The revenue for all United States stocks is 95.76% lower than that of the firm.
Moderna is rated top company in revenue category among related companies. Market size based on revenue of Biotechnology industry is now estimated at about 18.47 Billion. Moderna totals roughly 18.47 Billion in revenue claiming about 100% of stocks in Biotechnology industry.

Moderna Current Valuation Drivers

We derive many important indicators used in calculating different scores of Moderna from analyzing Moderna's financial statements. These drivers represent accounts that assess Moderna's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Moderna's important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(235.46 M)(359.55 M)(484 M)(651 M)13.52 B14.58 B
Earnings Before Interest Taxes and Depreciation Amortization USD(235.46 M)(359.55 M)(484 M)(651 M)13.52 B14.58 B
Earnings before Tax(256 M)(384.41 M)(515 M)(744 M)13.29 B14.33 B
Free Cash Flow(389.88 M)(436.63 M)(491 M)1.96 B13.34 B14.39 B
Invested Capital772.9 M1.11 B1.34 B531 M9.4 B10.14 B
Tangible Asset Value1.08 B1.96 B1.59 B7.34 B24.67 B26.62 B
Working Capital591.76 M1.34 B985.69 M1.91 B6.94 B7.49 B

Moderna Institutional Holders

Institutional Holdings refers to the ownership stake in Moderna that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Moderna's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Moderna's value.
Security TypeSharesValue
Modus Advisors LlcCommon Shares2.1 K304 K
Baillie Gifford CoCommon Shares45.6 M7.9 B
Blackrock IncCommon Shares28.7 M4.9 B
Vanguard Group IncCommon Shares27 M4.7 B
Flagship Pioneering IncCommon Shares17.6 MB
State Street CorpCommon Shares14.8 M2.6 B
Coatue Management LlcCommon Shares6.9 M1.2 B
Susquehanna International Group LlpCall Options4.2 M716.5 M
Susquehanna International Group LlpPut Options3.9 M669.8 M

Moderna Fundamentals

About Moderna Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Moderna's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Moderna using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Moderna based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2022
Deferred Revenue6.9 B7.4 B
Cost of Revenue2.6 B2.1 B
Revenues18.5 B19.9 B
Revenue to Assets 0.75  0.81 
Revenue Per Employee6.8 M7.4 M
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States and internationally. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. Moderna operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 2700 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Moderna without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Performance Analysis Now

   

Performance Analysis

Check effects of mean-variance optimization against your current asset allocation
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Moderna using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Moderna Piotroski F Score and Moderna Altman Z Score analysis. Note that the Moderna information on this page should be used as a complementary analysis to other Moderna's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.

Complementary Tools for Moderna Stock analysis

When running Moderna price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Is Moderna's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
2.02
Market Capitalization
61.9 B
Quarterly Revenue Growth YOY
2.13
Return On Assets
0.5
Return On Equity
1.4
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine Moderna value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.